ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between November 2, 2022, and December 19, 2024, of the March 25, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by March 25, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, defendants made overly positive statements regarding Novo Nordisk's phase 3 CagriSema study on obesity, specifically the "REDEFINE-1" trial [4] - Defendants failed to disclose critical information about the trial's dosing protocol, which was described as "flexible," allowing patients to modify their dosages [4] - The lawsuit claims that when the true details of the trial were revealed, investors suffered damages due to the misleading statements made by the defendants [4]